Genomics and Precision Medicine for Clinicians and Scientists in Hypertension

Hypertension

Volumn 69, Issue 4, 2017, Pages e10-e13

  Dominiczak, Anna ^a   Delles, Christian ^a   Padmanabhan, Sandosh ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; GLUCOCORTICOID; HEPSIN; LOOP DIURETIC AGENT; PROTEINASE; TAMM HORSFALL GLYCOPROTEIN; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ARTICLE; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; ESTIMATED GLOMERULAR FILTRATION RATE; GENOMICS; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; ISCHEMIC HEART DISEASE; LIDDLE SYNDROME; LUNG DISEASE; MALIGNANT NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOHYPOALDOSTERONISM; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; RESEARCH;

GENOMICS; HUMANS; HYPERTENSION; PRECISION MEDICINE; RESEARCH;

EID: 85012924080     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08252     Document Type: Article

References (26)

1. Harris MH, DuBois SG, Glade Bender JL, et al. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016;2:608-615. doi:10.1001/jamaoncol.2015.5689.
2. Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol. 2015;12:239-245. doi: 10.1038/nrclinonc.2015.26.
3. Seufferlein T, Mayerle J. Pancreatic cancer in 2015: precision medicine in pancreatic cancer-fact or fiction? Nat Rev Gastroenterol Hepatol. 2016;13:74-75. doi: 10.1038/nrgastro.2015.215.
4. Tasian SK, Loh ML, Hunger SP. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer. 2015;121:3577-3590. doi: 10.1002/cncr.29573.
5. Beltran H, Eng K, Mosquera JM, et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 2015;1:466-474. doi: 10.1001/jamaoncol.2015.1313.
6. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, Kim CF. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015;520:239-242. doi: 10.1038/nature14122.
7. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556.
8. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res. 2015;116:937-959. doi: 10.1161/ CIRCRESAHA.116.303647.
9. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678. doi: 10.1038/nature05911.
10. Newton-Cheh C, Johnson T, Gateva V, et al; Wellcome Trust Case Control Consortium. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41:666-676. doi: 10.1038/ ng.361.
11. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;41:677-687. doi: 10.1038/ ng.384.
12. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109.
13. Havulinna AS, Kettunen J, Ukkola O, Osmond C, Eriksson JG, Kesäniemi YA, Jula A, Peltonen L, Kontula K, Salomaa V, Newton-Cheh C. A blood pressure genetic risk score is a significant predictor of incident cardiovascular events in 32,669 individuals. Hypertension. 2013;61:987-994. doi: 10.1161/HYPERTENSIONAHA.111.00649.
14. Fox CS, Hall JL, Arnett DK, et al; American Heart Association Council on Functional Genomics and Translational Biology, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Quality of Care and Outcomes Research, and Council on Epidemiology and Prevention. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation. 2015;131:1715-1736. doi: 10.1161/ CIR.0000000000000211.
15. Surendran P, Drenos F, Young R, et al; CHARGE-Heart Failure Consortium; EchoGen Consortium; METASTROKE Consortium; GIANT Consortium; EPIC-InterAct Consortium; Lifelines Cohort Study; Wellcome Trust Case Control Consortium; Understanding Society Scientific Group; EPIC-CVD Consortium; CHARGE+ Exome Chip Blood Pressure Consortium; T2D-GENES Consortium; GoT2DGenes Consortium; ExomeBP Consortium; CHD Exome+ Consortium. Transancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat Genet. 2016;48:1151-1161. doi: 10.1038/ng.3654.
16. Ehret GB, Ferreira T, Chasman DI, et al; CHARGE-EchoGen Consortium; CHARGE-HF Consortium; Wellcome Trust Case Control Consortium. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet. 2016;48:1171-1184. doi: 10.1038/ng.3667.
17. Liu C, Kraja AT, Smith JA, et al; CHD Exome+ Consortium; ExomeBP Consortium; GoT2DGenes Consortium; T2D-GENES Consortium; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia; CKDGen Consortium. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat Genet. 2016;48:1162-1170. doi: 10.1038/ng.3660.
18. Padmanabhan S, Melander O, Johnson T, et al; Global BPgen Consortium. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet. 2010;6:e1001177. doi: 10.1371/journal.pgen.1001177.
19. Berglund G, Elmstähl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med. 1993;233:45-51.
20. Padmanabhan S, Graham L, Ferreri NR, Graham D, McBride M, Dominiczak AF. Uromodulin, an emerging novel pathway for blood pressure regulation and hypertension. Hypertension. 2014;64:918-923. doi: 10.1161/HYPERTENSIONAHA.114.03132.
21. Graham LA, Padmanabhan S, Fraser NJ, Kumar S, Bates JM, Raffi HS, Welsh P, Beattie W, Hao S, Leh S, Hultstrom M, Ferreri NR, Dominiczak AF, Graham D, McBride MW. Validation of uromodulin as a candidate gene for human essential hypertension. Hypertension. 2014;63:551-558. doi: 10.1161/HYPERTENSIONAHA.113.01423.
22. Trudu M, Janas S, Lanzani C, et al; Swiss Kidney Project on Genes in Hypertension (SKIPOGH) Team. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013;19:1655-1660. doi: 10.1038/ nm.3384.
23. Brunati M, Perucca S, Han L, et al. The serine protease hepsin mediates urinary secretion and polymerisation of Zona Pellucida domain protein uromodulin. Elife. 2015;4:e08887. doi: 10.7554/eLife.08887.
24. Renigunta A, Renigunta V, Saritas T, Decher N, Mutig K, Waldegger S. Tamm-Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and regulates its function. J Biol Chem. 2011;286:2224-2235. doi: 10.1074/jbc.M110.149880.
25. Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D. Aligning incentives to fulfil the promise of personalised medicine. Lancet. 2015;385:2118-2119. doi: 10.1016/S0140-6736(15)60722-X.
26. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-795. doi: 10.1056/NEJMp1500523.